Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, has announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter 2026 operating and financial results. The webcast, led by President and CEO Panna Sharma and members of the management team, will review results for the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company's RADR and Open-Medicine AI platforms. A replay will be available on the investor relations section of Lantern Pharma's website following the event.
The announcement comes at a pivotal time for Lantern, as the company continues to integrate its AI-driven approach into cancer therapy development. The RADR platform, which uses machine learning to analyze genomic and clinical data, has been central to Lantern's pipeline, which includes LP-184 (an acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (a cisplatin/ethacraplatin analog) currently in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
Beyond its clinical pipeline, Lantern has made strides in commercializing its AI capabilities. The company's withZeta.ai, a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community. This move represents a new revenue stream for Lantern, potentially diversifying its income beyond traditional drug development. The company also operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The webcast is expected to shed light on how these AI platforms are performing and how they might accelerate drug discovery and development. For investors, the call could provide clarity on the company's financial health and strategic direction, particularly as it navigates the costly and time-consuming process of clinical trials. Lantern's focus on AI-driven precision oncology positions it at the intersection of two high-growth fields: artificial intelligence and cancer therapeutics.
Lantern's announcement also highlights the broader trend of AI adoption in the pharmaceutical industry. By leveraging machine learning to identify patient populations most likely to respond to therapies, Lantern aims to increase the efficiency of clinical trials and improve patient outcomes. The availability of withZeta.ai to the wider biomedical community could further establish Lantern as a leader in AI-enabled drug development, potentially attracting partnerships and collaborations.
Investors and industry observers will be watching the webcast for updates on Lantern's clinical milestones, particularly the progress of its HARMONIC trial and the development of LP-184 in pediatric CNS cancers. Any positive data could significantly impact the company's valuation. Conversely, delays or setbacks could raise concerns about the viability of its pipeline.
As Lantern prepares to report its second-quarter results, the company's ability to balance its clinical ambitions with the commercialization of its AI platforms will be key. The webcast offers an opportunity for management to articulate how these pieces fit together and to reassure stakeholders of the company's growth trajectory.
For more information, visit https://ibn.fm/l80kv to view the full press release.
